Generating solutions

Lung cancer accounts for 14% of all diagnosed cancers in Canada from which 80% of patients will be tested for programmed cell death protein 1 (PD-L1) through the course of the disease. This project aims to develop PD-L1 Mass Spectrometry (MS)-based assays for use in immune-oncology. The Receptor, MRM Proteomics, in partnership with the academic leaders will develop two alternative analytical pipelines based on multiple reaction monitoring (MRM, for research purposes) and immuno MALDI (iMALDI technology, suitable for clinical diagnostics). The anticipated revenues for MRMP’s new PD-L1 kit is projected as $3.5 million over the first five years post project and with the addition of the iMALDI technology to 20% of the PD-L1 test kits would generate more than $250 million.